These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33021189)

  • 1. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
    Rand LZ; Kesselheim AS
    J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.
    Tantivess S; Teerawattananon Y; Mills A
    Pharmacoeconomics; 2009; 27(11):931-45. PubMed ID: 19888793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
    Rand LZ; Kesselheim AS
    Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
    Egilman AC; Rome BN; Kesselheim AS
    JAMA; 2023 Apr; 329(15):1283-1289. PubMed ID: 37071095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
    Michaeli DT; Mills M; Kanavos P
    Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods of international health technology assessment agencies for economic evaluations--a comparative analysis.
    Mathes T; Jacobs E; Morfeld JC; Pieper D
    BMC Health Serv Res; 2013 Sep; 13():371. PubMed ID: 24079858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.
    Kanavos P; Ferrario A; Vandoros S; Anderson GF
    Health Aff (Millwood); 2013 Apr; 32(4):753-61. PubMed ID: 23569056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
    Bendicksen L; Rome BN; Avorn J; Kesselheim AS
    Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK.
    Salas-Vega S; Bertling A; Mossialos E
    Health Policy; 2016 Oct; 120(10):1104-1114. PubMed ID: 27665497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment in Japan: a work in progress.
    Kamae I; Thwaites R; Hamada A; Fernandez JL
    J Med Econ; 2020 Apr; 23(4):317-322. PubMed ID: 31944134
    [No Abstract]   [Full Text] [Related]  

  • 16. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health technology assessment: decentralized and fragmented in the US compared to other countries.
    Perry S; Thamer M
    Health Policy; 1997 Jun; 40(3):177-98. PubMed ID: 10168751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.
    Drummond M; Jönsson B; Rutten F; Stargardt T
    Eur J Health Econ; 2011 Jun; 12(3):263-71. PubMed ID: 20803050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
    Pericleous L; Amin M; Goeree R
    J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
    Rocchi A; Mills F
    J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.